A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
CNBC
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Read the full story
This is a short summary. The complete article is published by CNBC.
Headline and summary aggregated from public news feeds. For information only — not financial advice.